Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes antitumour immunity in combination with radiotherapy
Malin Pedersen, Lisa C. Hubbard, Shane Foo, Anton Patrikeev, Antonio Rullan, Holly Baldock, Christian Mandl, Paolo Chetta, Jehanne Hassan, Isaac Dean, Naomi Guppy, Philippe Slos, Charleen Chan Wah Hak, Elizabeth S. Appleton, Emmanuel Christian Patin, , Kevin J Harrington
This study evaluates a second-generation STING agonist, BI-1703880, showing that combining it with radiotherapy enhances antitumour immunity and immune memory.
bioRxiv · Mar 25, 2026 · PreprintCancer Biology